Destiny Pharma (LSE:DEST) Additional Paid-In Capital : £39.57 Mil(As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Destiny Pharma Additional Paid-In Capital?

Destiny Pharma's quarterly additional paid-in capital increased from Dec. 2022 (£33.04 Mil) to Jun. 2023 (£39.57 Mil) but then stayed the same from Jun. 2023 (£39.57 Mil) to Dec. 2023 (£39.57 Mil).

Destiny Pharma's annual additional paid-in capital increased from Dec. 2021 (£27.09 Mil) to Dec. 2022 (£33.04 Mil) and increased from Dec. 2022 (£33.04 Mil) to Dec. 2023 (£39.57 Mil).

Destiny Pharma Additional Paid-In Capital Historical Data

The historical data trend for Destiny Pharma's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Destiny Pharma Additional Paid-In Capital Chart

Destiny Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

17.30

27.09

33.04

39.57

Destiny Pharma Semi-Annual Data
	Dec14	Dec15	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial												27.09	33.04	33.04	39.57	39.57

Destiny Pharma Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Destiny Pharma Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Destiny Pharma's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Destiny Pharma (LSE:DEST) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Destiny Pharma PLC (LSE:DEST) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

D89:Germany

Address

Unit 36, Sussex Innovation Centre, Science Park Square, Falmer, Brighton, GBR, BN1 9SB

Website

https://www.destinypharma.com

Destiny Pharma PLC is a clinical-stage biotechnology company which is focused on the development of medicines for the treatment of infectious disease. It is developing drugs for the prevention and treatment of infections caused by Antibiotic-Resistant (AR) bacteria. It is involved in developing XF-73 Dermal for the treatment of skin infections of antibiotic-resistant bacteria, XF-73 Nasal for prevention of post-surgical staphylococcal infection, XF Throat for prevention of staphylococcal hospital/ventilator-associated pneumonia infection.

Destiny Pharma (LSE:DEST) Headlines

No Headlines